Consideration of barriers to research: part 2

Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.

Consideration of barriers to research part 2: schedule 1 controlled drugs

Details

On 12 December 2022 the ACMD was commissioned by the Minister of State for Crime, Policing and Fire to provide advice to reduce barriers to research for all schedule 1 controlled drugs.

This follows ACMD advice in 2021 to reduce barriers to research for synthetic cannabinoid receptor agonists (SCRAs) (Consideration of barriers to research: part 1). After collecting evidence from the research community, the ACMD formulated several options to reduce barriers to research for schedule 1 controlled drugs in academia and industry.

The ACMD has recommended a series of options that could provide solutions in the short term, alongside further options for government to consider.